The Role of Hepatic Steatosis in Chronic Hepatitis B Infection

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.

•• Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92. This article is an authoritative review of the epidemiology, natural history, and treatment of hepatitis B.

Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49:S28–34.

Welch S, Chiang B, Shadday P, Brosgart CL. Estimated prevalence of chronic hepatitis B in foreign-born persons living in the United States by country/region of origin [abstract 853]. Hepatology. 2008;48:687A.

McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89:14–8.

Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886–95.

Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26:142–52.

Chen YC, Yeh ChuCM, CT LYF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1:267–73.

Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis. 2004;8:255–66.

Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.

Schuppan D, Gorrell MD, Klein T, et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver International. 2010;30:795–808.

Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol. 2010;16:1171–6.

Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5–13.

Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARγ. Gastroenterology. 2007;132:1955–67.

Kim KJ, Kim KH, Kim HH, et al. Hepatitis B virus X protein induces lipogenic transcription factor SREBP-1 and fatty acid synthase through the activation of nuclear receptor LXRα. Biochem J. 2008;416:219–30.

• Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–7. This article describes an original analysis examining the relationship between metabolic syndrome and liver cirrhosis.

Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–21.

• Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410–5. This article describes an original study with an analysis of the relationship between metabolic syndrome and liver-related mortality.

Altiparmak E, Koklu S, Yalinkilic M, et al. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol. 2005;11:3056–9.

Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007;27:607–11.

Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol. 2007;41:513–7.

Czaja AJ, Carpenter HA, Santrach PJ, et al. Host and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29:198–206.

Demir K, Akyuz F, Ozdil S, et al. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann Hepatol. 2007;6:92–6.

Giannattasio A, Cirillo F, Terlizzi V, et al. Hepatic steatosis is uncommon in children with chronic hepatitis B. J Clin Virol. 2009;46:360–2.

Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol. 2005;43:38–44.

Hung CH, Lee CM, Lu SN, et al. Hepatic steatosis with hepatitis B virus/hepatitis C virus dual infection. Hepatology. 2010;52:1521–2.

Lin YC, Hsiao ST, Chen JD. Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults. World J Gastroenterol. 2007;13:1805–10.

Mellen JS, Xia VW, Hashemzadeh M, et al. The clinical presentation of chronic hepatitis B virus infection in Asian Americans. J Clin Gastroenterol. 2010;44:364–70.

Minakari M, Molaei M, Shalmani HM, et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. J Gastroenterol Hepatol. 2009;21:512–6.

• Park SH, Kim DJ, Lee HY. Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection. Am J Gastroenterol. 2009;104:1135–9. This article describes an original study with analysis of metabolic and histologic parameters in a well-characterized nondiabetic cohort.

Peng D, Han Y, Ding H. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol. 2008;23:1082–8.

Persico M, Masarone M, La Mura V, et al. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol. 2009;15:462–6.

• Shi JP, Fan JG, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419–25. This article describes an original study with an analysis of the largest reported cohort of patients with chronic HBV infection undergoing liver biopsy with assessement of hepatic steatosis.

Siagris D, Vafiadis G, Michalaki M, et al. Serum adinopectin in chronic hepatitis C and B. J Viral Hepatitis. 2007;14:577–83.

Thomopoulos KC, Arvaniti V, Tsamantas AC, et al. Prevalence of hepatic steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006;18:233–7.

Tsochatzis E, Papatheodoridis GV, Manesis EK. Hepatic steatosis in chronic hepatitis B develop due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis. 2007;39:936–42.

Wang CC, Hsu CS, Liu CJ, et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008;23:779–82.

Yun JW, Cho YK, Park JH, et al. Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. Liver Int. 2009;29:878–83.

Zheng RD, Xu CR, Jiang L, et al. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci. 2010;7:272–7.

Brunt EM, Janney CG, DiBisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.

Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–7.

Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B (HBV) surface antigen in chronic HBV infection? Int J Obes. 2007;31:871–5.

WHO Expert Panel. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.

Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. New Engl J Med. 2008;359:2442–55.

Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. New Engl J Med. 2007;357:2576–88.

Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med. 2003;348:808–16.

Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med. 2006;354:1011–20.

Lim JK, Ayoub WS, Nguyen MH. Histologic disease in patients with chronic hepatitis B, hig HBV DNA, and normal alanine aminotransferase levels. Curr Hepatitis Rep. 2010;9:65–74.